Allogene Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Allogene Therapeutics announces its 2026 Annual Meeting, seeking shareholder approval to double authorized common stock to 800 million shares.
NASDAQ
Allogene Therapeutics, Inc. has filed a definitive proxy statement related to its upcoming shareholder meeting.
NASDAQ
DEF 14A: Allogene Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Allogene Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 18, 2025, featuring proposals for director elections, executive compensation advisory vote, and ratification of the independent accounting firm.
NASDAQ
Allogene Therapeutics has filed a definitive proxy statement related to its upcoming shareholder meeting.
NASDAQ
Allogene Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to vote on director elections, executive compensation, and auditor ratification.